Moreover, some studies reported that the baseline levels of sPD-L1 do not correlate with efficacy in NSCLC patients treated with anti-PD-(L1) immunotherapy [309,310,311]. This evidence concerns the gene SPDL1 and non-small cell lung carcinoma.